JP2011519037A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011519037A5 JP2011519037A5 JP2011506552A JP2011506552A JP2011519037A5 JP 2011519037 A5 JP2011519037 A5 JP 2011519037A5 JP 2011506552 A JP2011506552 A JP 2011506552A JP 2011506552 A JP2011506552 A JP 2011506552A JP 2011519037 A5 JP2011519037 A5 JP 2011519037A5
- Authority
- JP
- Japan
- Prior art keywords
- lipocalin
- level
- subject
- risk
- cardiovascular disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010051335 Lipocalin-2 Proteins 0.000 claims description 231
- 102000013519 Lipocalin-2 Human genes 0.000 claims description 230
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 104
- 238000000034 method Methods 0.000 claims description 70
- 239000003550 marker Substances 0.000 claims description 46
- 238000003556 assay Methods 0.000 claims description 36
- 238000011282 treatment Methods 0.000 claims description 35
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 30
- 238000012360 testing method Methods 0.000 claims description 26
- 208000010125 myocardial infarction Diseases 0.000 claims description 25
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 19
- 102100032752 C-reactive protein Human genes 0.000 claims description 19
- 102000003896 Myeloperoxidases Human genes 0.000 claims description 19
- 108090000235 Myeloperoxidases Proteins 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- 230000008901 benefit Effects 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 235000012000 cholesterol Nutrition 0.000 claims description 13
- 230000001965 increasing effect Effects 0.000 claims description 13
- 238000005259 measurement Methods 0.000 claims description 13
- 230000027455 binding Effects 0.000 claims description 12
- 210000002700 urine Anatomy 0.000 claims description 12
- 108091023037 Aptamer Proteins 0.000 claims description 10
- 239000005557 antagonist Substances 0.000 claims description 9
- 208000019622 heart disease Diseases 0.000 claims description 9
- 210000001124 body fluid Anatomy 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 5
- 239000010839 body fluid Substances 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 230000002485 urinary effect Effects 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- 201000010099 disease Diseases 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 239000000090 biomarker Substances 0.000 description 15
- 208000029078 coronary artery disease Diseases 0.000 description 15
- 238000003018 immunoassay Methods 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 238000001514 detection method Methods 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 102000019298 Lipocalin Human genes 0.000 description 6
- 108050006654 Lipocalin Proteins 0.000 description 6
- 108010004729 Phycoerythrin Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 108010004469 allophycocyanin Proteins 0.000 description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 238000002820 assay format Methods 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 239000003527 fibrinolytic agent Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 229940123900 Direct thrombin inhibitor Drugs 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 101001023834 Mus musculus Neutrophil gelatinase-associated lipocalin Proteins 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127218 antiplatelet drug Drugs 0.000 description 3
- 229960004676 antithrombotic agent Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- -1 or both) Proteins 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 108091006082 receptor inhibitors Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003868 thrombin inhibitor Substances 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010002388 Angina unstable Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 2
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 2
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 2
- 102000013382 Gelatinases Human genes 0.000 description 2
- 108010026132 Gelatinases Proteins 0.000 description 2
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 206010029155 Nephropathy toxic Diseases 0.000 description 2
- 101710147507 Neutrophil gelatinase-associated lipocalin Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000048176 Prostaglandin-D synthases Human genes 0.000 description 2
- 108030003866 Prostaglandin-D synthases Proteins 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 208000007814 Unstable Angina Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 108091022862 fatty acid binding Proteins 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000003547 immunosorbent Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007694 nephrotoxicity Effects 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 238000012502 risk assessment Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001138 tear Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 102000045205 Angiopoietin-Like Protein 4 Human genes 0.000 description 1
- 101710085845 Angiopoietin-related protein 4 Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 102100022954 Apolipoprotein D Human genes 0.000 description 1
- 108010025614 Apolipoproteins D Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 239000003154 D dimer Substances 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical group OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- 101000665882 Homo sapiens Retinol-binding protein 4 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102100035405 Neutrophil gelatinase-associated lipocalin Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 102100038246 Retinol-binding protein 4 Human genes 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 108010057517 Strep-avidin conjugated horseradish peroxidase Proteins 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012504 chromatography matrix Substances 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 102000047202 human LCN2 Human genes 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 239000000852 hydrogen donor Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000002587 lymphangiography Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000000101 novel biomarker Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940124272 protein stabilizer Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/113,056 US8030097B2 (en) | 2008-04-30 | 2008-04-30 | Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks |
| US12/113.056 | 2008-04-30 | ||
| PCT/CN2009/000405 WO2009132510A1 (en) | 2008-04-30 | 2009-04-16 | Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011519037A JP2011519037A (ja) | 2011-06-30 |
| JP2011519037A5 true JP2011519037A5 (https=) | 2013-06-13 |
| JP5687186B2 JP5687186B2 (ja) | 2015-03-18 |
Family
ID=41254765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011506552A Expired - Fee Related JP5687186B2 (ja) | 2008-04-30 | 2009-04-16 | 心臓及び発作（ｓｔｒｏｋｅ）のリスクのための予後診断及び診断マーカーとしてのリポカリン−２ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8030097B2 (https=) |
| EP (1) | EP2300048A4 (https=) |
| JP (1) | JP5687186B2 (https=) |
| CN (1) | CN102026655A (https=) |
| WO (1) | WO2009132510A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2240781T3 (en) | 2008-01-18 | 2018-03-26 | Harvard College | METHODS FOR DETECTING DISEASE OR STATE SIGNATURES IN BODY FLUIDS |
| WO2011014863A2 (en) * | 2009-07-31 | 2011-02-03 | Alt Eckhard U | Prophylaxis against cancer metastasis |
| KR20120101064A (ko) * | 2009-11-13 | 2012-09-12 | 비쥐 메디신, 인코포레이티드 | 심근 경색의 위험 인자 및 예측 |
| EP2534491B1 (en) * | 2010-02-10 | 2016-10-19 | Cleveland Heartlab LLC | Compositons and methods for predicting cardiovascular events |
| US8383580B2 (en) | 2010-06-10 | 2013-02-26 | The Regents Of The University Of Michigan | Methods of administering lipocalins to treat metabolic disorders and cardiovascular diseases |
| AU2011280997A1 (en) | 2010-07-23 | 2013-02-28 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
| CA2806304A1 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
| EP2596134B1 (en) | 2010-07-23 | 2020-04-08 | President and Fellows of Harvard College | Methods of detecting diseases or conditions using phagocytic cells |
| EP2596349B1 (en) | 2010-07-23 | 2017-12-13 | President and Fellows of Harvard College | Methods of detecting cardiovascular diseases or conditions |
| WO2012012693A2 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods for detecting signatures of disease or conditions in bodily fluids |
| ES2606140T3 (es) * | 2010-10-01 | 2017-03-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos para predecir la progresión y tratar una enfermedad renal crónica en un paciente |
| WO2012072820A1 (en) * | 2010-12-03 | 2012-06-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of heart failure |
| HUE030649T2 (en) * | 2011-02-22 | 2017-05-29 | Innavirvax | Procedure for Anticipating the Progress of HIV Disease |
| MX373248B (es) * | 2011-09-30 | 2020-05-11 | Somalogic Operating Co Inc | Prediccion de riesgo de evento cardiovascular y usos del mismo. |
| WO2013156867A2 (en) * | 2012-04-19 | 2013-10-24 | Inserm | Methods and pharmaceutical compositions for the treatment of hypertension |
| EP2861788B1 (en) | 2012-06-15 | 2018-10-10 | Progenity, Inc. | Methods of detecting diseases or conditions using circulating diseased cells |
| WO2013188846A1 (en) | 2012-06-15 | 2013-12-19 | Harry Stylli | Methods of detecting diseases or conditions |
| US9594083B2 (en) * | 2012-09-28 | 2017-03-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method for the treatment of cardiovascular fibrosis |
| US11585814B2 (en) | 2013-03-09 | 2023-02-21 | Immunis.Ai, Inc. | Methods of detecting prostate cancer |
| EP2965077B1 (en) | 2013-03-09 | 2022-07-13 | Harry Stylli | Methods of detecting cancer |
| MA40636A (fr) | 2014-09-11 | 2015-09-11 | Colleen Kelly | Procédés pour détecter le cancer de la prostate |
| CA3054083A1 (en) * | 2017-02-20 | 2018-08-23 | The Regents Of The University Of California | Serologic assay for silent brain ischemia |
| KR102443523B1 (ko) * | 2020-11-24 | 2022-09-15 | 경상국립대학교산학협력단 | 리포칼린-2 단백질을 이용한 발작에 의한 뇌신경세포 사멸 예측 또는 진단을 위한 정보제공방법 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2306192B1 (en) * | 2003-12-05 | 2015-10-14 | The Cleveland Clinic Foundation | Risk Markers For Cardiovascular Disease |
| US20050244892A1 (en) * | 2004-02-27 | 2005-11-03 | Lazar Mitchell A | Resistin as a marker and therapeutic target for cardiovascular disease |
| CN101010001A (zh) * | 2004-05-06 | 2007-08-01 | 哥伦比亚大学受托人 | Ngal用于减少和改善局部缺血和肾中毒损伤 |
| CA2565701A1 (en) * | 2004-05-06 | 2005-11-17 | Jonathan M. Barasch | Ngal for reduction and amelioration of ischemic and nephrotoxic injuries |
| EP1844339A2 (en) * | 2005-02-04 | 2007-10-17 | The Scripps Research Institute | Dyslipoproteinemia associated with venous thrombosis |
| US20070037232A1 (en) * | 2005-03-31 | 2007-02-15 | Barasch Jonathan M | Detection of NGAL in chronic renal disease |
| JP2010502985A (ja) * | 2006-09-05 | 2010-01-28 | ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド | インスリン感受性の制御におけるリポカリン２の使用 |
| KR100819122B1 (ko) * | 2006-09-30 | 2008-04-04 | 남명진 | 췌장암 진단용 키트 |
| US7645616B2 (en) * | 2006-10-20 | 2010-01-12 | The University Of Hong Kong | Use of lipocalin-2 as a diagnostic marker and therapeutic target |
| EP2095106B1 (en) * | 2006-11-14 | 2013-03-20 | Alere San Diego, Inc. | Methods and compositions for diagnosis and prognosis of renal artery stenosis |
| WO2008060607A2 (en) * | 2006-11-14 | 2008-05-22 | Biosite Incorporated | Methods and compositions for monitoring and risk prediction in cardiorenal syndrome |
-
2008
- 2008-04-30 US US12/113,056 patent/US8030097B2/en active Active
-
2009
- 2009-04-16 CN CN2009801160607A patent/CN102026655A/zh active Pending
- 2009-04-16 JP JP2011506552A patent/JP5687186B2/ja not_active Expired - Fee Related
- 2009-04-16 EP EP09737621A patent/EP2300048A4/en not_active Withdrawn
- 2009-04-16 WO PCT/CN2009/000405 patent/WO2009132510A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5687186B2 (ja) | 心臓及び発作（ｓｔｒｏｋｅ）のリスクのための予後診断及び診断マーカーとしてのリポカリン−２ | |
| JP2011519037A5 (https=) | ||
| KR101678703B1 (ko) | 갈렉틴-３ 면역검정 | |
| US8361732B2 (en) | Combination of sPLA2 activity and oxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event | |
| EP2095106A2 (en) | Methods and compositions for diagnosis and prognosis of renal artery stenosis | |
| EP2279419A1 (en) | Gdf-15 as biomarker in type 1 diabetes | |
| JP4689651B2 (ja) | 急性肺塞栓症用生化学マーカー | |
| KR20170072215A (ko) | 생물마커 및 예측 방법 | |
| US9347959B2 (en) | Oxidative biomarkers in predicting risk of stroke, transient ischemic attack (TIA) and peripheral arterial disease (PAD) | |
| JP4927093B2 (ja) | 可溶性アジポネクチンレセプターペプチドの検出ならびに診断および治療における使用 | |
| JP2011521248A (ja) | メタボリックシンドロームを有する患者及び有しない患者のリスク分析 | |
| JP7399431B2 (ja) | 動脈硬化及び動脈硬化関連疾患マーカー | |
| US20110082349A1 (en) | Means and methods for determining the arteriosclerotic stenosis using inflammatory biomarkers | |
| JP5369118B2 (ja) | バイオマーカーｐｌｇｆを用いてアテローム性動脈硬化負荷を決定する手段及び方法 | |
| US8383355B2 (en) | Combination of sPLA2 type IIA mass and OXPL/APOB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event | |
| WO2011038786A1 (en) | COMBINATION OF sPLA2 TYPE IIA MASS AND OXPL/APOB CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT | |
| EP2385372A1 (en) | Kidney disease in normal and abnormal pregnancy | |
| HK1118902A (en) | Biochemical markers for acute pulmonary embolism | |
| HK1182443B (en) | Prediction and recognition of acute kidney injury after surgery | |
| HK1182443A1 (zh) | 手术後急性肾损伤的预测和识别 | |
| WO2010018123A1 (en) | Retinol binding protein 4 as a marker of peripheral insulin resistance in type 1 diabetes |